Ovarian cancer recurrent

• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra … Recruiting
  2023-509598-22-01 6 2025-05-13 "Oncology - Breast cancer"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M … Recruiting
  2024-516841-38-00 4 2025-01-09 "recurrent ovarian cancer wild type for germline and somatic "
• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 "Recurrent ovarian cancer"
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting
  2022-501904-83-00 7 2023-09-11 "Ovarian Cancer"
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other … Recruiting
  2024-510783-23-00 7 2020-10-29 "Fallopian Tube Cancer"
• This is a phase 2 open label clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with … Recruitment ended
  2024-512138-13-00 4 2023-09-27 "Recurrent ovarian cancer positive for MAGE-A4 in human leuko"
• PERCEPTION Recruitment ended
  2023-508155-40-00 4 2022-01-25 "recurrent platin sensitive low-grade serous ovarian-, fallop"
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Recruitment ended
  2023-506177-35-00 11 2021-10-23 "Ovarian, fallopian tube, or primary peritoneal carcinoma."
• A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM … Recruitment ended
  2024-516986-35-00 4 2021-09-06 "Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)"
• A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo … Recruitment ended
  2024-516959-40-00 4 2021-08-17 "This trial evaluates the efficacy and safety of Mirvetuximab"
• Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla … Recruitment ended
  2024-516096-32-00 4 2021-08-05 "Platinum sensitive recurrent ovarian cancer"
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl … Recruitment ended
  2023-505102-42-00 5 2014-12-18 "Solid Malignant Tumors"
• Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended
  2024-515196-35-00 3 2022-09-29 "Platinum-Resistant Ovarian Cance"

Showing 1–15 of 15 trials